Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects with Prior Corneal Refractive Surgery

Did you have prior corneal refractive surgery (LASIK, PRK or LASEK), and now have cataracts? If so, you may be eligible to participate in a research study for a new investigational intraocular lens (IOL) that allows your eye doctor to adjust the power of the lens after it has been implanted in your eye.

Please swipe/click through the presentation below to get a better understanding of how prior refractive surgery can influence cataract surgery, and how RxSight’s Light Adjustable Lens works!

View Fullscreen

>
<

Study Details

RxSight, Inc. is conducting a research study for a new investigational intraocular lens (IOL) that allows your eye doctor to adjust the power of the lens after it has been implanted in your eye.

“Investigational” means that the device being tested has not been approved by the United States Food and Drug Administration (FDA). Before any IOL can be approved and made available to the general public, it must go through clinical research studies to make sure the treatment works safely and effectively.

The purpose of this study is to evaluate the safety and effectiveness of RxSight’s Light Adjustable Lens and Light Delivery Device (LDD) in eyes that have had prior corneal refractive surgery, such as LASIK, PRK, or LASEK, and now have cataracts.

Approximately 120 male and female subjects at a maximum of six different centers within the United States will participate in this study which will analyze how well RxSight’s Light Adjustable Lens improves vision after the natural cataract lens has been removed and replaced.

You may qualify for this study if:

  • You are between 40 and 80 years old
  • You currently have cataracts in both eyes which is affecting your vision
  • You had prior corneal refractive surgery (LASIK, PRK, LASEK) in both eyes

A formal consent process and ocular screening are required before decisions can be made about your enrollment and willingness to be involved with this study. See below for a list of participating centers.


Study Locations

To learn more about this study, you or your doctor may contact the study research staff using the information provided below.

Kansas
Discover Vision Centers
Leawood, Kansas, United States, 66211
Contact: Clinical Research Coordinator for Dr. John Doane 816-350-6903
Principal Investigator: John F Doane, MD

Ohio
Cleveland Eye Clinic
Brecksville, Ohio, United States, 44141
Contact: Erin Kus-Kreidler 216-503-6535 ekus-kreidler@clevelandeyeclinic.com
Principal Investigator: William F Wiley, MD

South Dakota
Vance Thompson Vision Clinic
Sioux Falls, South Dakota, United States, 57108
Contact: Keeley Puls, Director of Research, CCRC 605-361-3937
Principal Investigator: Vance Thompson, MD, FACS

Texas
Slade & Baker Vision
Houston, Texas, United States, 77027
Contact: Research Department 713-626-5544 info@visiontexas.com
Principal Investigator: Steven Slade, MD, FACS

Focal Point Vision
San Antonio, Texas, United States, 78209
Contact: Lisa Navarro 210-614-3600 ext. 118 navarro@focalpointvision.com
Principal Investigator: James D Lehmann, MD

Utah
The Eye Institute of Utah
Salt Lake City, Utah, United States, 84107
Contact: Laurie Adams 801-266-2283
Principal Investigator: Robert J Cionni, MD
 

RxSight, Inc.
Contact: David Goffredo 949-421-5463 ext 300 dgoffredo@rxsight.com